Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Ono Pharmaceutical discovers, develops, and sells prescription medicines, mainly in Japan, with a growing push into global markets.
Ono Pharmaceutical is a Japanese drugmaker. It researches, develops, and sells prescription medicines, and for most of its history the bulk of its business has been in its home market of Japan, where it sells to hospitals, clinics, and pharmacies through the country's national health system.
Its most famous product is Opdivo, a cancer immunotherapy that helps the body's own immune system attack tumors. Opdivo became a huge global seller after Ono partnered with Bristol Myers Squibb to develop and market it outside Japan, and the royalties and profit shares from that deal turned Ono from a mid-sized local player into a company with real international earnings. Ono also sells pain and central-nervous-system medicines, and it has been building out its pipeline in oncology and other specialty areas to reduce its dependence on any single drug. The business model is classic pharma: spend years and large sums on research, win regulatory approval, then earn money selling patented medicines at high prices until patents expire and cheaper generics arrive. That makes the pipeline the real engine — a few big wins can fund everything else, and a few failures can hurt badly. Ono's challenge is the same one every drugmaker faces: keep replacing older products with new ones before the old ones lose protection.
Ono uses its cash to fund research and development, strike partnerships and licensing deals, and return money to shareholders through dividends and share buybacks. It is headquartered in Osaka, and its fortunes now depend on both defending its cancer franchise and proving it can discover the next big medicine on its own.
Saved answer · last researched 15 Nov 2026